Journal of Nuclear Medicine: Introduction

Journal of Nuclear Medicine

Volumn 52, Issue SUPPL. 2, 2011, Pages

  Czernin, Johannes ^a   Weber, Wolfgang A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

COMPUTER ASSISTED EMISSION TOMOGRAPHY; EDITORIAL; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HUMAN; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; PATIENT CARE; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; SCIENTIFIC LITERATURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 83755206278     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.097071     Document Type: Editorial

References (16)

1. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369-1379. (Pubitemid 30643379)
2. Delbeke D, Segall GM. Status of and trends in nuclear medicine in the United States. J Nucl Med. 2011;52(suppl):24S-28S.
3. Dondi M, Kashyap R, Paez D, et al. Trends in nuclear medicine in developing countries. J Nucl Med. 2011;52(suppl):16S-23S.
4. Schelbert R. Nuclear medicine at a crossroads. J Nucl Med. 2011;52(suppl):10S-15S.
5. Larson SM. The Janus Project: the remaking of nuclear medicine and radiology. J Nucl Med. 2011;52(suppl):3S-9S.
6. Ware RE, Hicks RJ. Doing more harm than good? Do systematic reviews of PET by health technology assessment agencies provide an appraisal of the evidence that is closer to the truth than the primary data supporting its use? J Nucl Med. 2011;52(suppl):64S-73S.
7. Weber WA. Is there evidence for evidence-based medical imaging? J Nucl Med. 2011;52(suppl):74S-76S.
8. Vach W, Høilund-Carlsen PF, Gerke O, Weber WA. Generating evidence for clinical benefit of PET/CT in diagnosing cancer patients. J Nucl Med. 2011;52(suppl):77S-85S.
9. Yang Y, Czernin J. Contribution of imaging to cancer care costs. J Nucl Med. 2011;52(suppl):86S-92S.
10. Graham MM, Menda Y. Radiopeptide imaging and therapy in the United States. J Nucl Med. 2011;52(suppl):56S-63S.
11. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide imaging and therapy in Europe. J Nucl Med. 2011;52(suppl):42S-55S.
12. Beyer T, Czernin J, Freudenberg LS. Variations in clinical PET/CT operations: results of an international survey of active PET/CT users. J Nucl Med. 2011;52:303-310.
13. Graham MM, Badawi RD, Wahl RL. Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med. 2011;52:311-317.
14. 18F-FDG PET/CT for treatment response assessments. J Nucl Med. 2011;52(suppl):93S-100S.
15. Schwaiger M, Wester H-J. How many PET tracers do we need? J Nucl Med. 2011;52(suppl):36S-41S.
16. Freudenberg LS, Beyer T. Subjective perception of radiation risk. J Nucl Med. 2011;52(suppl):29S-35S.